Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282175 | 0.93 | THRA (0.75) | THRATHRB | |
| SCHEMBL19982616 | 0.92 | THRB (0.70) | THRATHRB | |
| SCHEMBL285715 | 0.88 | THRA (1.00) | THRATHRB | |
| SCHEMBL13381642 | 0.87 | THRA (0.70) | THRATHRB | |
| SCHEMBL3160909 | 0.87 | THRA (1.00) | THRATHRB | |
| SCHEMBL282015 | 0.87 | THRB (0.79) | THRATHRB | |
| SCHEMBL13867770 | 0.87 | THRA (0.60) | THRATHRB | |
| SCHEMBL282255 | 0.86 | THRB (0.58) | THRATHRB | |
| SCHEMBL4203016 | 0.84 | THRA (0.84) | THRATHRB | |
| SCHEMBL18774709 | 0.83 | THRA (0.82) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255080-A1 | METHOD OF REDUCING THYROID-ASSOCIATED SIDE EFFECTS | TSHR, TPO, THRA | THRA 3/4885THRB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.